Does that controversial new opioid work as advertised?
It was, for obvious reasons, an unpopular decision: Last month the FDA approved an opioid painkiller that is 10 times more potent than fentanyl, a move critics called tone-deaf in light of a nationwide crisis that has claimed the lives of thousands.
The FDA has defended the decision, pointing out that the product, called Dsuvia, is meant for use on the battlefield, not for distribution at a local pharmacy. But STAT’s Ed Silverman dug into the drug’s clinical data and consulted experts. His conclusion: The FDA approval should give you pause.